Skip to main
RANI

RANI Stock Forecast & Price Target

RANI Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Rani Therapeutics Holdings Inc. has developed the proprietary RaniPill capsule, which aims to provide an innovative oral delivery method for biologics, thus offering a substantial improvement over traditional injection methods. The company is well-capitalized with financial resources extending through 2028, allowing for continued investment in its internal pipeline, including promising data from its RT-114 candidate, which shows favorable bioavailability and tolerability. Additionally, the increasing M&A activity in the oral delivery and obesity therapy space further enhances Rani Therapeutics' market potential and investor interest in the company's growth trajectory.

Bears say

Rani Therapeutics Holdings Inc faces significant challenges that contribute to a negative outlook on its stock, including potential limitations in gaining market share and the pressure of unfavorable pricing upon market entry. The company has experienced management turnover, which may disrupt clinical development efforts and negatively impact overall share performance. Additionally, concerns surrounding FDA approval for key devices, market adoption of the RaniPill technology, and a recent capital raise leading to share dilution further complicate the financial landscape for Rani Therapeutics.

RANI has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Rani Therapeutics Holdings and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Rani Therapeutics Holdings (RANI) Forecast

Analysts have given RANI a Strong Buy based on their latest research and market trends.

According to 4 analysts, RANI has a Strong Buy consensus rating as of Apr 23, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Rani Therapeutics Holdings (RANI)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.